2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
11
Osteoporosis
8
Colorectal Neoplasms
4
Bone Diseases, Metabolic
4
Prostatic Neoplasms
3
Pain
3
Vitamin D Deficiency
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Leukemia
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Paclitaxel-induced Neuropathy
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myocardial Ischemia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Motor Activity
1
Lung Neoplasms
1
Kidney Neoplasms
1
Inflammation
1
Heart Diseases
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Calcium
×
Clear all
NCT00172068
2009-12-23
MRD-1
Novartis
Phase 2
Terminated
96 enrolled